News Search Results
May 06, 2024, 23:30 ET Health-tech innovator Remidio achieves unprecedented scale in the US with its revolutionary retinal solutions
University of Virginia, and several others. University of Virginia's Assistant Professor of Ophthalmology, Dr. Arjun Dirghangi has this to add, "Remidio's FOP-NM is easier to use, easy to train on. We have gotten good images,
More news about: Remidio Innovative Solutions
May 06, 2024, 20:06 ET Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products
More news about: Innovent Biologics
May 06, 2024, 16:10 ET Injectsense First-in-Human Glaucoma Device Study Approved by Ethics Committee at Centro de la Vision Clinic
validation milestones of the past few years," said Dr. Myron Yanoff, MD, FAAO, Adjunct Professor, Department of Ophthalmology at the University of Pennsylvania, and former Director of the Scheie Eye Institute. "Once the technology is shown
More news about: Injectsense
May 06, 2024, 11:04 ET ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events
presence at the American Society for Immunology (AAI) from May 3rd to 7th, the Association for Research in Vision and Ophthalmology (ARVO) from May 5th to 9th, and CYTO 2024 presented by the International Society for Advancement
More news about: ThinkCyte Inc.
May 06, 2024, 08:00 ET HTL Biotechnology, market leader in biopolymers, acquires the Modern Meadow's human recombinant collagen platform for beauty and biomedical applications
ambition, through this acquisition, is to drive innovation in the company's historical segments, including aesthetic medicine, rheumatology, and ophthalmology, as well as explore new therapeutic areas. The synergy between HTL Biotechnology's high-quality GMP biofermentation expertise and this new platform
More news about: HTL Biotechnology
May 05, 2024, 14:10 ET TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
lamp examination, fundoscopy, and optical coherence tomography. Withhold or permanently discontinue BALVERSA® based on severity and/or ophthalmology exam findings. Hyperphosphatemia and Soft Tissue Mineralization – BALVERSA® can cause hyperphosphatemia leading to soft
More news about: Johnson & Johnson
May 03, 2024, 10:00 ET RevOpsis Welcomes Dr. Emmett Cunningham to Strategic Advisory Board
Cunningham's prestigious career includes several prominent board memberships with various noteworthy biopharmaceutical companies including several ophthalmology focused companies such as Annexon Biosciences, GrayBug Vision, Nacuity Pharmaceuticals, and Eyconis, where he is co-founder and executive chair.
More news about: RevOpsis
May 03, 2024, 08:00 ET Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024
& Johnson will also have an interactive Specialty Ophthalmology Medical Affairs exhibit booth (location #1539) at the ARVO annual meeting. For more information about Johnson & Johnson's investigational portfolio in Specialty Ophthalmology, please visit
More news about: Johnson & Johnson Innovative Medicine
May 03, 2024, 07:00 ET HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
Fischer ME, et al. Dry eye in the Beaver Dam Offspring Study: Prevalence, Risk Factors, and Health-related Quality of Life. American Journal of Ophthalmology. 2014 Apr; 157(4):799-806. About VELOS-4 VELOS-4 is a US-based multicenter, randomized,
More news about: HanAll Biopharma
May 02, 2024, 16:30 ET Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
today that nine scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, being held from May 5 – 9 in Seattle, Washington.
More news about: Kodiak Sciences Inc.
May 02, 2024, 07:00 ET Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
Trial (STARLIGHT)Abstract/Poster Number: B0094Session Type: Poster SessionSession Title: Pediatric Ophthalmology and Inherited Eye DiseasesSession Date: May 8, 2024 Session Time: 2:15 – 4:00 p.m. PTLocation: Exhibit
More news about: Nanoscope Therapeutics
May 02, 2024, 07:00 ET InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
More news about: InMode LTD
May 01, 2024, 10:18 ET MYRA VISION'S CALIBREYE™ TITRATABLE GLAUCOMA THERAPY™ SURGICAL SYSTEM SHOWCASED AT OPHTHALMOLOGY CONFERENCES, RECEIVING BEST PAPER AWARD AND RECOGNITION OF FUTURE PROMISE IN GLAUCOMA CARE
advances," stated Dr. Keith Barton, Moorfields Eye Hospital, Professor of Ophthalmology at the UCL Institute of Ophthalmology and Co-Founder/Co-Chair of the Ophthalmology Futures Forums and International Glaucoma Surgery Registry, who subsequently presented the first-in-human
More news about: Myra Vision, Inc.
May 01, 2024, 08:30 ET Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences
development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced its participation at key upcoming ophthalmology conferences to discuss the Company's clinical development efforts in dry age-related macular degeneration (dry AMD), including progression of lead
More news about: Stealth BioTherapeutics Inc.
May 01, 2024, 08:00 ET Ora, Inc. to showcase latest technologies and research at ARVO 2024, convene groundbreaking ophthalmic symposium Dry Horizons
ophthalmic pharmaceutical and device development, today announced its participation as a major exhibitor in the Association for Research in Vision and Ophthalmology
More news about: Ora, Inc.
Apr 30, 2024, 11:00 ET Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations
with current agents such as aflibercept and faricimab," said Quan Dong Nguyen, MD, MSc, FARVO, FASRS, Professor of Ophthalmology (Retina and Uveitis) at the Byers Eye Institute, and Professor of Medicine and Professor of Pediatrics at Stanford University
More news about: Eluminex Biosciences
Apr 30, 2024, 09:00 ET FDA clears first fully autonomous AI for portable diabetic retinopathy screening
Our science is evidently the strongest in this space and we're proud to make such unbelievable impact." Dr. Ianchulev, Professor of Ophthalmology at New York Eye and Ear of Mount Sinai and Board member of AEYE Health, says, "This is perhaps the most exciting
More news about: AEYE Health
Apr 30, 2024, 07:00 ET HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161
More news about: HanAll Biopharma
Apr 30, 2024, 00:30 ET Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announces the appointment of Dr. Samuel Zhang as its Global Chief Business Officer
More news about: Innovent Biologics
Apr 29, 2024, 07:00 ET Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits
Ophthalmology Innovation Source (OIS) Retina Innovation Summit, both taking place in Seattle, Washington. The management
More news about: Nanoscope Therapeutics
Apr 25, 2024, 09:15 ET RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment
the Rev-Mod platform enables swift and efficient design of multispecific biologics to address unmet needs in major therapeutic areas including ophthalmology, oncology, and immune-mediated diseases. About RevOpsis TherapeuticsFounded in 2018, RevOpsis Therapeutics is a privately
More news about: RevOpsis
Apr 25, 2024, 09:00 ET Leerink Partners Adds Industry Veteran Andrew Gitkin to Healthcare Investment Banking Team
focus on ophthalmology and robotic surgery. Mr. Gitkin will be based in the firm's Miami office and will report to Dr. Dan Dubin, Global Co-Head of Investment Banking. "Andrew's expertise in M&A advisory for ophthalmology and robotic
More news about: Leerink Partners
Apr 25, 2024, 07:00 ET Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
Ho MD, FACS is Attending Surgeon and Director of Retina Research and Co-Director of the Retina Service of Wills Eye Hospital, Professor of Ophthalmology at Thomas Jefferson University and partner of Mid Atlantic Retina. He maintains special interests in macular diseases,
More news about: Nanoscope Therapeutics
Apr 24, 2024, 21:59 ET Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that about 20 accepted abstracts of clinical data from multiple trials in relation to multiple novel mono-/bi-specific
More news about: Innovent Biologics
Apr 22, 2024, 19:25 ET PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
findings on its innovative ocular drug delivery platform at the upcoming conference, Association for Research in Vision and Ophthalmology (ARVO), the world's largest ophthalmology conference which will be held from May 5th to 9th, 2024 in Seattle,
More news about: PharmAbcine